Details

Autor(en) / Beteiligte

• Santacruz, Rodrigo
• Villamor, Neus
• Aymerich, Marta
• Martínez-Trillos, Alejandra
• López, Cristina
• Navarro, Alba
• Rozman, María
• Beà, Sílvia
• Royo, Cristina
• Cazorla, Maite
• Colomer, Dolors
• Giné, Eva
• Pinyol, Magda
• Puente, Xose S
• López-Otín, Carlos
• Campo, Elías
• López-Guillermo, Armando
• Delgado, Julio

Titel

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy

Ist Teil von

• Haematologica (Roma), 2014-05, Vol.99 (5), p.873

Ort / Verlag

Italy

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• A proportion of patients with chronic lymphocytic leukemia achieve a minimal residual disease negative status after therapy. We retrospectively evaluated the impact of minimal residual disease on the outcome of 255 consecutive patients receiving any front-line therapy in the context of a detailed prognostic evaluation, including assessment of IGHV, TP53, NOTCH1 and SF3B1 mutations. The median follow-up was 73 months (range, 2-202) from disease evaluation. The median treatment-free survival durations for patients achieving a complete response without or with minimal residual disease, a partial response and no response were 76, 40, 11 and 11 months, respectively (P<0.001). Multivariate analysis revealed that three variables had a significant impact on treatment-free survival: minimal residual disease (P<0.001), IGHV status (P<0.001) and β2-microglobulin levels (P=0.012). With regards to overall survival, factors predictive of an unfavorable outcome were minimal residual disease positivity (P=0.014), together with advanced age (P<0.001), unmutated IGHV status (P=0.001), TP53 mutations (P<0.001) and elevated levels of β2-microglobulin (P=0.003). In conclusion, for patients requiring front-line therapy, achievement of minimal residual disease negativity is associated with significantly prolonged treatment-free and overall survival irrespective of other prognostic markers or treatment administered.